185
Participants
Start Date
August 12, 2022
Primary Completion Date
August 18, 2023
Study Completion Date
August 18, 2023
CV0501 (3 μg)
Study vaccine was administered as a single intramuscular injection.
CV0501 (6 μg)
Study vaccine was administered as a single intramuscular injection.
CV0501 (12 μg)
Study vaccine was administered as a single intramuscular injection.
CV0501 (25 μg)
Study vaccine was administered as a single intramuscular injection.
CV0501 (50 μg)
Study vaccine was administered as a single intramuscular injection.
CV0501 (100 μg)
Study vaccine was administered as a single intramuscular injection.
CV0501 (200 μg)
Study vaccine was administered as a single intramuscular injection.
GSK Investigational Site, Sydney
GSK Investigational Site, Brookvale
GSK Investigational Site, Merewether
GSK Investigational Site, Wollongong
GSK Investigational Site, Cavite
GSK Investigational Site, Iloilo City
GSK Investigational Site, Binghamton
GSK Investigational Site, Rockville
GSK Investigational Site, Savannah
GSK Investigational Site, Melbourne
GSK Investigational Site, Hollywood
GSK Investigational Site, Cincinnati
GSK Investigational Site, Omaha
GSK Investigational Site, Norfolk
GSK Investigational Site, Sacramento
GSK Investigational Site, Peoria
GSK Investigational Site, Metairie
Lead Sponsor
GlaxoSmithKline
INDUSTRY